KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average (2016 - 2025)

Emergent BioSolutions' Equity Average history spans 15 years, with the latest figure at $552.6 million for Q4 2025.

  • For Q4 2025, Equity Average rose 11.49% year-over-year to $552.6 million; the TTM value through Dec 2025 reached $552.6 million, up 11.49%, while the annual FY2025 figure was $502.7 million, 11.19% down from the prior year.
  • Equity Average reached $552.6 million in Q4 2025 per EBS's latest filing, down from $559.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.6 billion in Q1 2022 to a low of $447.4 million in Q3 2024.
  • Average Equity Average over 5 years is $1.0 billion, with a median of $954.2 million recorded in 2023.
  • Peak YoY movement for Equity Average: skyrocketed 37.28% in 2021, then plummeted 52.26% in 2023.
  • A 5-year view of Equity Average shows it stood at $1.6 billion in 2021, then dropped by 10.0% to $1.4 billion in 2022, then crashed by 52.26% to $673.2 million in 2023, then fell by 26.39% to $495.6 million in 2024, then increased by 11.49% to $552.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Equity Average are $552.6 million (Q4 2025), $559.4 million (Q3 2025), and $544.4 million (Q2 2025).